CITIUS ONCOLOGY, INC. (CTOR) - Dilution Analysis

S-3 filing: The filing covers the potential resale of up to 32,931,482 shares of common stock by selling stockholders, consisting of shares underlying various warrants and a conversion option.

10-Q filing | 100.0M shares outstanding

8-K filing: Citius Oncology, Inc. entered into a warrant inducement agreement, a Third Amendment to Promissory Note, and a Loan and Security Agreement on May 5, 2026. ($11.5M proceeds)

S-3 filing: This prospectus relates to the sale or other disposition from time to time of (i) up to 21,656,620 shares of our common stock issuable upon the exercise of warrants (the "Warrants"), (ii) up to 15,299,358 shares of our common stock issuable upon the exercise of Pre-Funded Warrants (the "Pre-Funded Warrants"), and (iii) up to 2,859,501 shares of our common stock issuable upon the exercise of warrants issued to placement agents (the "Placement Agent Warrants") all held by the selling stockholders named in this prospectus (the "Selling Stockholders"), including their transferees, pledgees, donees or successors.

10-K filing | 84.8M shares outstanding

8-K filing: Citius Oncology, Inc. completed a registered direct offering and concurrent private placement, selling 1,284,404 shares of common stock at $1.09 per share and issuing pre-funded warrants to purchase up to 15,229,358 shares, resulting in gross proceeds of approximately $18.0 million.

S-3 filing: The company may offer and sell from time to time up to $200,000,000 of its shares of common stock, shares of preferred stock, debt securities, warrants, rights to purchase common stock, preferred stock, debt securities or units, in one or more offerings in amounts, at prices and on terms that it will determine at the time of offering.

10-Q filing | 71.6M shares outstanding

8-K filing: Citius Oncology, Inc. completed a public offering of 6,818,182 shares of common stock and warrants to purchase up to 6,818,182 shares at a combined price of $1.32 per unit, resulting in net proceeds of approximately $7.44 million.

S-1 filing: This is an offering of up to $15 million of shares of Common Stock (or Pre-Funded Warrant in lieu thereof) and Warrants to purchase up to $15 million of shares of Common Stock by Citius Oncology Inc.

S-1/A filing: The filing is an S-1/A amendment for an offering of common stock, warrants, and pre-funded warrants with Maxim Group LLC as the placement agent.

10-Q filing | 71.6M shares outstanding

10-Q filing | 71.6M shares outstanding

10-K filing | 68.1M shares outstanding

8-K filing: TenX issued 119,500 shares of Common Stock to the Sponsor for amounts outstanding under promissory notes and Citius Pharma issued a promissory note to the Sponsor which converted into 128,854 shares of Company Common Stock.

10-Q filing | 2.4M shares outstanding

8-K filing: Holders of 4,297,828 TenX Ordinary Shares exercised their rights to have such shares redeemed for approximately $11.46 per share, totaling $49,265,965.44. ($49.27M proceeds)

8-K filing: TenX Keane Acquisition redeemed 2,287,923 ordinary shares for cash at $10.90 per share, totaling approximately $24.9 million, and subsequently made additional payments of $268,645 to cover the difference based on an adjusted redemption price of $11.02 per share. ($24.9M proceeds)

10-Q filing | 6.7M shares outstanding

10-K filing | 6.6M shares outstanding

8-K filing: TenX Keane Acquisition's shareholders approved an extension to the date by which the Company has to consummate a business combination, and Citius Pharma deposited $200,000 into the Trust Account for the first extension period in connection with a merger agreement. ($24.9M proceeds)

10-Q filing | 8.9M shares outstanding

8-K filing: TenX Keane Acquisition entered into a Merger Agreement with Citius Pharmaceuticals and Citius Oncology, where Merger Sub will merge with Citius Oncology, resulting in the issuance of 67,500,000 shares of New Citius Oncology Common Stock to holders of Citius Oncology capital stock. ($675.0M proceeds)

10-Q filing | 8.9M shares outstanding

10-Q filing | 8.9M shares outstanding

10-K filing | 8.9M shares outstanding

10-Q filing | 8.9M shares outstanding

8-K filing: TenX Keane Acquisition consummated its initial public offering of 6,600,000 units at $10.00 per unit, generating gross proceeds of $66,000,000, and a private placement of 394,000 units to the Sponsor at $10.00 per unit, generating gross proceeds of $3,940,000. ($69.94M proceeds)

8-K filing: TenX Keane Acquisition consummated its initial public offering of 6,600,000 units at $10.00 per unit, generating gross proceeds of $66,000,000, and simultaneously consummated a private placement of 394,000 units to the Sponsor at $10.00 per unit, generating total proceeds of $3,940,000. ($69.94M proceeds)

S-1/A filing: TenX Keane Acquisition is offering 6,000,000 units at $10.00 per unit, each consisting of one ordinary share and one right, in an initial public offering. The sponsor has agreed to purchase 370,000 private placement units at $10.00 per unit.

S-1/A filing: TenX Keane Acquisition is offering 6,000,000 units at $10.00 per unit in an initial public offering, with each unit consisting of one ordinary share and one right, and the sponsor has agreed to purchase additional units in a private placement.

S-1/A filing: TenX Keane Acquisition is a blank check company planning an initial public offering of 6,000,000 units at $10.00 per unit, with each unit consisting of one ordinary share and one right to receive one-tenth of one ordinary share upon consummation of an initial business combination.

S-1/A filing: Initial public offering of units, each consisting of one ordinary share and one right, by TenX Keane Acquisition, a blank check company, with a proposed offering amount of $60,000,000.

S-1/A filing: The company is offering 6,000,000 units, each consisting of one ordinary share and one right to receive one-tenth of one ordinary share upon consummation of the initial Business Combination, at an offering price of $10.00 per Firm Unit.

S-1/A filing: Initial public offering of units of a blank check company, each unit consisting of one ordinary share and one right to receive one-tenth of one ordinary share upon consummation of an initial business combination.

S-1/A filing: TenX Keane Acquisition is offering 5,000,000 units at $10.00 per unit for a total of $50,000,000.

S-1/A filing: Initial public offering of 5,000,000 units at $10.00 per unit for a total of $50,000,000. Each unit consists of one Class A ordinary share and one right to receive one-tenth of one Class A ordinary share upon consummation of an initial business combination.

S-1 filing: Initial public offering of 5,000,000 units at $10.00 per unit for a total of $50,000,000.